BioPharma Dive October 28, 2024
Ned Pagliarulo

Novartis will pay the biotechnology company $150 million upfront to gain rights to an early-stage molecular glue degrader aimed at immune-mediated diseases.

Dive Brief:

  • Novartis will pay $150 million to gain rights to “molecular glue degraders” being developed by biotechnology company Monte Rosa Therapeutics to target an immune signaling protein, known as VAV1, that has long been considered “undruggable.”
  • The deal, announced by the companies Monday morning, could yield up to $2.1 billion in further payments by Novartis to Monte Rosa should the licensed research reach certain development, regulatory and sales milestones.
  • Molecular glue degraders are small molecule drugs that join together a target protein with an enzyme responsible for flagging cellular detritus for disposal. In Monte Rosa’s case,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Pharma / Biotech
Related Articles:
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
GLP-1 drug coverage for obesity making inroads with large employers: Mercer
44% of large employers cover weight loss drugs for obesity: Mercer

Share This Article